{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:22:59Z","timestamp":1791559379656,"version":"4.3.4"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Ophthalmol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Secukinumab is a monoclonal antibody that selectively neutralizes interleukin-17A and has shown efficacy in the treatment of psoriatic arthritis, psoriasis, and axial spondyloarthritis. Its use in non-anterior non-infectious uveitis is controversial, with evidence generally not supporting its effectiveness in these conditions. However, the role of secukinumab in anterior non-infectious uveitis remains unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Case series. Five patients with biological therapy-refractory non-infectious anterior uveitis who were treated with secukinumab were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All 5 patients experienced a uveitis flare-up during treatment, and secukinumab failed to induce long-term remission in 2 of these patients, who also had uncontrolled systemic disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Secukinumab failed to prevent uveitis flare-up in these patients with biological therapy-refractory disease. Further studies are necessary to determine the potential role of secukinumab in the treatment of anterior uveitis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fopht.2025.1491981","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T07:08:05Z","timestamp":1740640085000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Secukinumab in refractory non-infectious anterior uveitis"],"prefix":"10.3389","volume":"5","author":[{"given":"Otto M.","family":"Olivas-Vergara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Hernanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo E.","family":"Borges-Deniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredeswinda","family":"Romero-Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Sanchez-Pernaute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Carre\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215356","article-title":"The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies","volume":"78","author":"McGonagle","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000466","article-title":"Cytokines in uveitis","volume":"29","author":"Weinstein","year":"2018","journal-title":"Curr Opin Ophthalmol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.12.033","article-title":"Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy","volume":"122","author":"Letko","year":"2015","journal-title":"Ophthalmology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210931","article-title":"Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register","volume":"76","author":"Lie","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B6","article-title":"Efficacy of anti-tumour necrosis factor-\u03b1 monoclonal antibodies in patients with non-infectious anterior uveitis","volume":"37","author":"Fabiani","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-eular.4474","article-title":"SAT0270 Low incidence of both new-onset and flares of uveitis in secukinumab-treated patients with ankylosing spondylitis: clinical trial and post-marketing safety analysis","volume":"77","author":"Deodhar","year":"2018","journal-title":"Ann Rheumatic Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220420","article-title":"Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter","volume":"80","author":"Lindstr\u00f6m","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2011.05.002","article-title":"Consenso SER\u00a0sobre la gesti\u00f3n de riesgo del tratamiento con terapias biol\u00f3gicas en pacientes con\u00a0enfermedades reum\u00e1ticas","volume":"7","author":"Reino","year":"2011","journal-title":"Reumatol Cl\u00edn"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13922","article-title":"Secukinumab in HLA-B27 associated uveitis","volume":"49","author":"Miserocchi","year":"2021","journal-title":"Clin Exp Ophthalmol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051914-021944","article-title":"Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases","volume":"67","author":"Fragoulis","year":"2016","journal-title":"Annu Rev Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1186\/s13075-014-0426-z","article-title":"Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy","volume":"16","author":"van Baarsen","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225933","article-title":"Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b\/3 trials","volume":"83","author":"Brown","year":"2024","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Ophthalmology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fopht.2025.1491981\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T07:08:10Z","timestamp":1740640090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fopht.2025.1491981\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":14,"alternative-id":["10.3389\/fopht.2025.1491981"],"URL":"https:\/\/doi.org\/10.3389\/fopht.2025.1491981","relation":{},"ISSN":["2674-0826"],"issn-type":[{"value":"2674-0826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"article-number":"1491981"}}